Stock News

Stock Update (NASDAQ:ARIA): ARIAD Pharmaceuticals, Inc. Announces Results of Preclinical Studies on Brigatinib at the AACR Annual Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113) at …

Stock Update (NASDAQ:PCLN): Booking.com Announces Support of New Commitments in Europe

Today Booking.com, an operating business of Priceline Group Inc (NASDAQ:PCLN) announced its support of recent decisions by the National Competition Authorities in France, Italy …

Company Update (NASDAQ:GWPH): GW Pharmaceuticals PLC-ADR Initiates Second Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome

GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it …

Stock Update (NASDAQ:CAMP): CalAmp Corp. Acquires Crashboxx to Further Propel Its Insurance Telematics Strategy

CalAmp Corp. (NASDAQ:CAMP), a leading provider of wireless products, services and solutions, announced today that it has acquired privately held Crashboxx™, an early stage …

Company Update (NYSE:P): Entertainment and Music Veterans Tim Leiweke and Roger Faxon to Join Pandora Board of Directors

Pandora Media Inc (NYSE:P), the leading internet radio service, announced that Tim Leiweke has been elected and Roger Faxon has been nominated for election …

Stock Update (NASDAQ:PPHM): Data Presented at AACR Demonstrate Peregrine Pharmaceuticals’ Bavituximab Induces Immune Activation in PD-L1 Negative NSCLC Tumors

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the presentation of data from clinical translational studies of the company’s phosphatidylserine (PS)-targeting immunotherapy bavituximab. Initial data from a …

Stock Update (NYSE MKT:RNN): Rexahn Identifies RX-3117 Biomarker Presents Data at the 2015 AACR Annual Meeting

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today presents preclinical data on …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc.’s Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced preclinical results that further support varlilumab’s expansion into combination studies with PD-1 inhibitors.

Stock Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc. Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the AACR Annual Meeting

Ligand Pharmaceuticals Incorporated Inc. (NASDAQ:LGND) partner TG Therapeutics, Inc.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts